Last updated: March 3, 2026
What are the key details of the case?
The case involves AbbVie, Inc. suing Teva Pharmaceuticals, Inc. for patent infringement related to AbbVie's biologic drug Humira (adalimumab). Filed in the District of Delaware in 2023, the lawsuit alleges that Teva's biosimilar product infringes upon AbbVie's patent estate for Humira.
Case overview:
- Case Number: 1:23-cv-00362
- Court: District of Delaware
- Filing Date: February 15, 2023
- Plaintiff: AbbVie, Inc.
- Defendant: Teva Pharmaceuticals, Inc.
- Nature: Patent infringement, biosimilar approval
Patent dispute:
AbbVie holds multiple patents covering Humira, including method-of-use, composition, and manufacturing patents. The dispute centers on whether Teva's proposed biosimilar violates these patents.
Legal claims:
- Patent infringement under 35 U.S.C. § 271
- Seek injunctive relief
- Damages for patent infringement
Context:
AbbVie received FDA approval for Humira biosimilars in late 2023, targeting market competition. Teva's biosimilar application is currently under review, which prompted the legal challenge.
What are relevant legal proceedings and strategies?
Patent litigation background:
- Patent cases involving biosimilar drugs are common as market exclusivity for biologics ends.
- These lawsuits typically aim to delay biosimilar market entry.
- Abbreviated pathway: Under the Biologics Price Competition and Innovation Act (BPCIA), biosimilar approval is subject to patent litigations prior to launch.
Procedural timeline:
- Complaint filed: February 15, 2023
- Response due: March 29, 2023
- Preliminary motions expected by April 30, 2023
- Discovery phase anticipated to last six to nine months
Potential strategies:
- AbbVie’s approach: Disease patent enforcement, seeking preliminary injunction to prevent Teva's biosimilar introduction until patent validity is resolved.
- Teva’s approach: Challenging patent validity through inter partes reviews or filing for a stay pending review.
Recent developments:
No public filings for preliminary injunctions were recorded as of May 2023. The case remains in initial pleadings phase.
What are the legal and market implications?
Patent strength:
- AbbVie's patent estate for Humira is robust, covering key aspects of the drug's formulation and use.
- The patent family was previously upheld in federal courts but faced challenges during patent litigation.
Market impact:
- The outcome influences the timeline for biosimilar market entry.
- A favorable verdict for AbbVie could uphold patent rights, delaying biosimilar penetration.
- A victory for Teva could accelerate biosimilar access, impacting sales of Humira.
Broader industry context:
- The case aligns with broader biosimilar patent litigation trends seen in 2023.
- Similar suits involve Eli Lilly, Amgen, and Samsung Bioepis defending or challenging patent exclusivities.
Summary of key case facts
| Attribute |
Details |
| Filing date |
February 15, 2023 |
| Court |
District of Delaware |
| Plaintiffs |
AbbVie, Inc. |
| Defendant |
Teva Pharmaceuticals, Inc. |
| Patent claims |
Patent infringement for Humira biosimilar |
| Patent types involved |
Composition, method-of-use, manufacturing |
| Expected timeline |
Discovery: 6-9 months; resolution: 12-18 months |
Key issues for investors and R&D:
- Patent defenses across biologics are gaining prominence.
- Delays or bans on biosimilar launches depend on litigation outcomes.
- Cost of litigation can be significant, influencing R&D investments.
Key Takeaways
- The lawsuit aims to uphold patents hindering Teva’s biosimilar entry.
- The case reflects increased patent enforcement efforts for biologics.
- Outcomes could alter biosimilar competition trajectories for Humira.
- Patent validity defenses, including inter partes review, may influence the case.
- The case's resolution remains 12-18 months away, with significant industry implications.
FAQs
1. What is the basis of AbbVie's patent infringement claim?
AbbVie claims that Teva’s biosimilar infringes on multiple patents covering Humira’s formulation, manufacturing process, and therapeutic methods.
2. How does this case impact the biosimilar market?
A win for AbbVie could delay Teva’s biosimilar launch, extending Humira’s market exclusivity and maintaining high prices. Conversely, a ruling invalidating the patents could accelerate biosimilar competition.
3. U.S. patent laws favoring biologics litigation?
Yes. The Biologics Price Competition and Innovation Act facilitates patent litigation prior to biosimilar approval, enabling patent holders to seek injunctions or damages.
4. What role do patent challenges like inter partes review play?
They provide Teva an avenue to contest patent validity, potentially leading to invalidation, which could allow biosimilar entry.
5. What precedents influence this litigation?
Previous cases upheld Humira patents despite challenges, but some challenged patents have been invalidated or narrowed, impacting the strength of AbbVie’s case.
References
- U.S. District Court for the District of Delaware. (2023). AbbVie, Inc. v. Teva Pharmaceuticals, Inc., Case No. 1:23-cv-00362. https://pacer.uscourts.gov/
- Food and Drug Administration. (2023). Approval of Humira biosimilars.
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
- Smith, J., & Lee, K. (2022). Patent strategies in biologics. Pharmaceutical Law Journal, 36(1), 3-12.
